SYMBOL:

    Up to 100 tickers separated by a space
Site Map FAQ Contact us Home Personalize
Company
Industry
Earnings
US Markets
Most Active
Portfolio
Tools
ETFs
Ratings
GENMARK DIAGNOSTICS
(NQNM:GNMK Last Sale: 11.74 +0)
Fundamentals Charts Tech Analysis Industry Earnings
Company Profile   Details

Company Web Site
NQNM: (GNMK : $11.74)
$720,051 million Market Cap at Market Close, July 1, 2022
Medical Products SubIndustry up .00% / Health Industry up .00% Today
Research Report Earnings Snapshot - Last 10/30/18
Fact Sheet
Financial Statements
Peer Comparison
Annual Reports

Jon Faiz Kayyem, CEO, Steven Kemper, CFO
Molecular diagnostics. Detects and measures DNA and RNA targets to diagnose disease and to optimize the treatment of patients, focused on developing and commercializing eSensor detection technology. Cystic Fibrosis Genotyping Test, Warfarin Sensitivity Test and Thrombophilia Risk Test have received FDA clearance. Predecessor company, Clinical Micro Sensors, acquired by Motorola in 2000 for $280 million. IPO at $6 May 27, 2010. Raised $27.6 million, selling 4.6 million shares, 39% of the outstanding. Lead Manager: Piper Jaffray.
Historical Charts    Technical Analysis
No Historical Data available for GNMK

Type of Stock Symbol Last Sale Last Close Net +/- % +/- Low High Volume 52wk Low 52wk High Shares(M)
Common GNMK $11.74 $11.74 0 .0 $11.11 $12.42 3,778,395 $11.11 $12.42 61,333,121
Capitalization
Earnings Summary ()
*** No Earnings Available***
-10121
Common Stock $720,050,841

A
Google



QUICK NAVIGATION SITE SEARCH   Enter Keyword:
   
Home    Subscribe    Browser Help    Subscriber Services    B-to-B    Banks    Brokerage    Telco    Site Map    Legal    Contact/Email
Copyright © 1996 - 2024 Stock Smart with all rights reserved
Feed is currently being brought back up
Provided by Nanex